Purpose: To evaluate the efficacy, recurrence rate, and long-term complications of topical mitomycin C (MMC) 0.02% for conjunctival-corneal intraepithelial neoplasia (CCIN).
Methods: A prospective, nonrandomized, noncontrolled study was conducted of patients with primary or recurrent CCIN treated with topical MMC 0.02%, four times per day, for 28 consecutive days. The main outcome measures were complete resolution of the neoplasia by slit-lamp examination and cytology 1 month after treatment, tumor recurrence, and long-term complications.
Results: Between June 1999 and September 2005, 23 patients were included. Eighteen had primary CCIN (group 1) and 5 had recurrent CCIN (group 2). The mean follow-up was 46 months in group 1 and 54 months in group 2. All patients were treated with MMC 0.02% for 28 consecutive days. Complete resolution of the lesion was achieved in all patients after 1 month of treatment. Recurrence occurred in 1 patient (4.3%) after 24 months of treatment. Four patients developed corneal erosion (17.4%), 2 of them with primary CCIN and 2 with recurrent CCIN. Corneal erosion occurred 4 to 24 months after treatment and was treated successfully. The probability for corneal erosions by the log-rank test was equal for both groups (p = 0.1705).
Conclusions: The use of topical MMC 0.02% for 28 consecutive days to treat primary or recurrent CCIN was effective and showed a low recurrence rate. Corneal erosion occurred in 17.4% of cases and can occur as late as 24 months after treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/IOP.0b013e3181ac4c39 | DOI Listing |
Am J Ophthalmol
December 2024
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China. Electronic address:
Purpose: To investigate the ability to quantify fundus curvature and detect posterior staphyloma using widefield optical coherence tomography (OCT).
Design: Cross-sectional diagnostic evaluation.
Subjects And Participants: 205 highly myopic eyes of 205 participants.
3 Biotech
January 2025
Plant Cell Biotechnology (PCBT) Department, Central Food Technological Research Institute (CFTRI), Mysuru, 570 020 India.
Unlabelled: The present study evaluated the effects of 5-methyltetrahydrofolate (5-MTHF) and aqueous extract on diabetes. An in silico docking study with select bioactive compounds showed strong binding affinities of folates with glucose metabolism-related proteins. In vitro assay showed 5-MTHF's superior inhibitory activity on alpha-amylase compared to folic acid.
View Article and Find Full Text PDFCureus
October 2024
Pulmonology, Khalifa Gul Nawaz Teaching Hospital, Bannu Medical College Medical Teaching Institute, Bannu, PAK.
BMC Geriatr
October 2024
Emergency Department, Erasmus MC, Rotterdam, The Netherlands.
Background: Older adults account for a large proportion of hospital admissions. In this study we aim to bridge a gap between medical and psychosocial factors in predicting hospitalisation.
Methods: Demographic and social characteristics of community-dwelling pre-frail and frail older people were collected by questionnaires every six months during a two year follow-up.
Am J Ophthalmol
September 2024
From the Ophthalmology Department (M.M.C., F.B., F.G., E.C., S.R.), "Fondazione Policlinico Universitario A. Gemelli, IRCCS", Rome, Italy; Ophthalmology Department (M.M.C., F.B., F.G., E.C., T.C., S.R.), Catholic University "Sacro Cuore", Rome, Italy; Consiglio Nazionale delle Ricerche (S.R.), Istituto di Neuroscienze, Pisa, Italy.
Purpose: To assess choroidal changes associated to optic disc pit maculopathy (ODP-M) and their evolution after surgical treatment.
Design: Multicentric retrospective case series.
Methods: An analysis of 42 patients affected by unilateral ODP-M undergoing surgical treatment between 2013 and 2023 was conducted.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!